OBJECTIVES: To investigate the effect of treatment with atenolol on 5-year survival in cats with preclinical hypertrophic cardiomyopathy (HCM). ANIMALS: 63 Client-owned cats with preclinical HCM and 31 healthy control cats. METHODS: Prospective, observational, open-label, clinical cohort study. Cats with HCM were diagnosed by echocardiography, treated with atenolol (6.25-12.5 mg q12h, PO; n = 42) or untreated (n = 21), and were observed for 5 years after enrollment. The study end point was death from any cause. Cats of similar body weight, age, gender, and breed without evidence of heart disease were studied concurrently and served as controls. RESULTS: During the observational period, 27 cats with HCM died; 14 (22%) due to cardiac disease and 13 (21%) due to non-cardiac disease. Ten control cats (32%) died of non-cardiac disease. There was no significant difference (P = 0.307) in all-cause mortality between control and HCM. Cardiac mortality was higher in cats with HCM compared to control cats (P = 0.005). There was no significant difference in all-cause mortality (P = 0.729) and cardiac mortality (P = 0.897) between cats with HCM treated or untreated with atenolol. Age and left atrial size at diagnosis were the only predictors of 5-year outcome. CONCLUSIONS: Our study failed to demonstrate an effect of atenolol on 5-year survival in cats with preclinical HCM.
OBJECTIVES: To investigate the effect of treatment with atenolol on 5-year survival in cats with preclinical hypertrophic cardiomyopathy (HCM). ANIMALS: 63 Client-owned cats with preclinical HCM and 31 healthy control cats. METHODS: Prospective, observational, open-label, clinical cohort study. Cats with HCM were diagnosed by echocardiography, treated with atenolol (6.25-12.5 mg q12h, PO; n = 42) or untreated (n = 21), and were observed for 5 years after enrollment. The study end point was death from any cause. Cats of similar body weight, age, gender, and breed without evidence of heart disease were studied concurrently and served as controls. RESULTS: During the observational period, 27 cats with HCM died; 14 (22%) due to cardiac disease and 13 (21%) due to non-cardiac disease. Ten control cats (32%) died of non-cardiac disease. There was no significant difference (P = 0.307) in all-cause mortality between control and HCM. Cardiac mortality was higher in cats with HCM compared to control cats (P = 0.005). There was no significant difference in all-cause mortality (P = 0.729) and cardiac mortality (P = 0.897) between cats with HCM treated or untreated with atenolol. Age and left atrial size at diagnosis were the only predictors of 5-year outcome. CONCLUSIONS: Our study failed to demonstrate an effect of atenolol on 5-year survival in cats with preclinical HCM.
Authors: Philip R Fox; Bruce W Keene; Kenneth Lamb; Karsten A Schober; Valerie Chetboul; Virginia Luis Fuentes; Gerhard Wess; Jessie Rose Payne; Daniel F Hogan; Alison Motsinger-Reif; Jens Häggström; Emilie Trehiou-Sechi; Deborah M Fine-Ferreira; Reid K Nakamura; Pamela M Lee; Manreet K Singh; Wendy A Ware; Jonathan A Abbott; Geoffrey Culshaw; Sabine Riesen; Michele Borgarelli; Michael B Lesser; Nicole Van Israël; Etienne Côté; John E Rush; Barret Bulmer; Roberto A Santilli; Andrea C Vollmar; Maribeth J Bossbaly; Nadine Quick; Claudio Bussadori; Janice M Bright; Amara H Estrada; Dan G Ohad; Maria Josefa Fernández-Del Palacio; Jenifer Lunney Brayley; Denise S Schwartz; Christina M Bové; Sonya G Gordon; Seung Woo Jung; Paola Brambilla; N Sydney Moïse; Christopher D Stauthammer; Rebecca L Stepien; Cecilia Quintavalla; Christophe Amberger; Ferenc Manczur; Yong-Wei Hung; Remo Lobetti; Marie De Swarte; Alice Tamborini; Carmel T Mooney; Mark A Oyama; Andrey Komolov; Yoko Fujii; Romain Pariaut; Masami Uechi; Victoria Yukie Tachika Ohara Journal: J Vet Intern Med Date: 2018-04-16 Impact factor: 3.333
Authors: Jonathan N King; Mike Martin; Valérie Chetboul; Luca Ferasin; Anne T French; Günther Strehlau; Wolfgang Seewald; Sarah G W Smith; Simon T Swift; Susan L Roberts; Andrea M Harvey; Christopher J L Little; Sarah M A Caney; Kerry E Simpson; Andrew H Sparkes; Eleanor J Mardell; Eric Bomassi; Claude Muller; John P Sauvage; Armelle Diquélou; Matthias A Schneider; Laurence J Brown; David D Clarke; Jean-Francois Rousselot Journal: J Vet Intern Med Date: 2019-09-27 Impact factor: 3.333
Authors: Virginia Luis Fuentes; Jonathan Abbott; Valérie Chetboul; Etienne Côté; Philip R Fox; Jens Häggström; Mark D Kittleson; Karsten Schober; Joshua A Stern Journal: J Vet Intern Med Date: 2020-04-03 Impact factor: 3.333
Authors: Ingrid van Hoek; Hannah Hodgkiss-Geere; Elizabeth F Bode; Julie Hamilton-Elliott; Paul Mõtsküla; Valentina Palermo; Yolanda Martinez Pereira; Geoff J Culshaw; Jeremy Laxalde; Joanna Dukes-McEwan Journal: J Vet Intern Med Date: 2020-10-29 Impact factor: 3.333